Carcinogenesis, Vol. 21, No. 7, 1271-1279,
July 2000
© 2000 Oxford University Press
Review |
Retinoids in chemoprevention and differentiation therapy
Laboratory of Cellular Carcinogenesis and Tumor Promotion, Division of Basic Sciences and
1 Laboratory of Chemoprevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4255 and
2 FDA, CFSAN, OSN, 200 C Street SW, Washington, DC 20204, USA
Retinoids are essential for the maintenance of epithelial differentiation. As such, they play a fundamental role in chemoprevention of epithelial carcinogenesis and in differentiation therapy. Physiological retinoic acid is obtained through two oxidation steps from dietary retinol, i.e. retinol
retinalretinoic acid. The latter retinalretinoic acid step is irreversible and eventually marks disposal of this essential nutrient, through cytochrome P450-dependent oxidative steps. Mutant mice deficient in aryl hydrocarbon receptor (AHR) accumulate retinyl palmitate, retinol and retinoic acid. This suggests a direct connection between the AHR and retinoid homeostasis. Retinoids control gene expression through the nuclear retinoic acid receptors (RARs) 
, ß and 
and 9-cis-retinoic acid receptors , ß and , which bind with high affinity the natural ligands all-trans-retinoic acid and 9-cis-retinoic acid, respectively. Retinoids are effective chemopreventive agents against skin, head and neck, breast, liver and other forms of cancer. Differentiation therapy of acute promyelocytic leukemia (APL) is based on the ability of retinoic acid to induce differentiation of leukemic promyelocytes. Patients with relapsed, retinoid-resistant APL are now being treated with arsenic oxide, which results in apoptosis of the leukemic cells. Interestingly, induction of differentiation in promyelocytes and consequent remission of APL following retinoid therapy depends on expression of a chimeric PML–RAR fusion protein resulting from a t(15;17) chromosomal translocation. This protein functions as a dominant negative against the function of both PML and RARs and its overexpression is able to recreate the phenotypes of the disease in transgenic mice. The development of new, more effective and less toxic retinoids, alone or in combination with other drugs, may provide additional avenues for cancer chemoprevention and differentiation therapy.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Tanaka, K. S. Suh, A. M. Lo, and L. M. De Luca p21WAF1/CIP1 Is a Common Transcriptional Target of Retinoid Receptors: PLEIOTROPIC REGULATORY MECHANISM THROUGH RETINOIC ACID RECEPTOR (RAR)/RETINOID X RECEPTOR (RXR) HETERODIMER AND RXR/RXR HOMODIMER J. Biol. Chem., October 12, 2007; 282(41): 29987 - 29997. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Mei, Q. Xia, L. Chen, M. M. Moore, P. P. Fu, and T. Chen Photomutagenicity of Retinyl Palmitate by Ultraviolet A Irradiation in Mouse Lymphoma Cells Toxicol. Sci., November 1, 2005; 88(1): 142 - 149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-Y. Lee, Y. S. Chang, J.-Y. Han, D. D. Liu, J. J. Lee, R. Lotan, M. R. Spitz, and W. K. Hong Effects of 9-cis-Retinoic Acid on the Insulin-Like Growth Factor Axis in Former Smokers J. Clin. Oncol., July 1, 2005; 23(19): 4439 - 4449. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Osanai and M. Petkovich Expression of the Retinoic Acid-Metabolizing Enzyme CYP26A1 Limits Programmed Cell Death Mol. Pharmacol., May 1, 2005; 67(5): 1808 - 1817. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. C. Maley, B. J. Reid, and S. Forrest Cancer Prevention Strategies That Address the Evolutionary Dynamics of Neoplastic Cells: Simulating Benign Cell Boosters and Selection for Chemosensitivity Cancer Epidemiol. Biomarkers Prev., August 1, 2004; 13(8): 1375 - 1384. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Murphy, C. M. Villano, R. Dorn, and L. A. White Interaction between the Aryl Hydrocarbon Receptor and Retinoic Acid Pathways Increases Matrix Metalloproteinase-1 Expression in Keratinocytes J. Biol. Chem., June 11, 2004; 279(24): 25284 - 25293. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Y. Park, I. J. Cho, and S. G. Kim Transactivation of the PPAR-Responsive Enhancer Module in Chemopreventive Glutathione S-Transferase Gene by the Peroxisome Proliferator-Activated Receptor-{gamma} and Retinoid X Receptor Heterodimer Cancer Res., May 15, 2004; 64(10): 3701 - 3713. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Orita, M. Hirose, S. Takahashi, K. Imaida, N. Ito, K. Shudo, H. Ohigashi, A. Murakami, and T. Shirai Modifying Effects of 1'-Acetoxychavicol Acetate (ACA) and the Novel Synthetic Retinoids Re-80, Am-580 and Am-55P in a Two-Stage Carcinogenesis Model in Female Rats Toxicol Pathol, February 1, 2004; 32(2): 250 - 257. [Abstract] [PDF]
|
|
|
|
|
|
F. Andreola, G. P. Hayhurst, G. Luo, S. S. Ferguson, F. J. Gonzalez, J. A. Goldstein, and L. M. De Luca Mouse Liver CYP2C39 Is a Novel Retinoic Acid 4-Hydroxylase: ITS DOWN-REGULATION OFFERS A MOLECULAR BASIS FOR LIVER RETINOID ACCUMULATION AND FIBROSIS IN ARYL HYDROCARBON RECEPTOR-NULL MICE J. Biol. Chem., January 30, 2004; 279(5): 3434 - 3438. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Benko, J. D. Love, M. Beladi, J. W. R. Schwabe, and L. Nagy Molecular Determinants of the Balance between Co-repressor and Co-activator Recruitment to the Retinoic Acid Receptor J. Biol. Chem., October 31, 2003; 278(44): 43797 - 43806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Hansen, D. Brown, V. Virador, T. Tanaka, F. Andreola, K. Strain, B. Dancheck, R. Riley, J. M. Arbeit, L. M. De Luca, et al. A PMLRARA Transgene Results in a Retinoid-deficient Phenotype Associated with Enhanced Susceptibility to Skin Tumorigenesis Cancer Res., September 1, 2003; 63(17): 5257 - 5265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Matsushima-Nishiwaki, M. Okuno, Y. Takano, S. Kojima, S. L. Friedman, and H. Moriwaki Molecular mechanism for growth suppression of human hepatocellular carcinoma cells by acyclic retinoid Carcinogenesis, August 1, 2003; 24(8): 1353 - 1359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zhuang, T. N. Faria, P. Chambon, and L. J. Gudas Identification and Characterization of Retinoic Acid Receptor {beta}2 Target Genes in F9 Teratocarcinoma Cells Mol. Cancer Res., June 1, 2003; 1(8): 619 - 630. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Pirkmaier, K. Yuen, J. Hendley, M. J. O'Connell, and D. Germain Cyclin D1 Overexpression Sensitizes Breast Cancer Cells to Fenretinide Clin. Cancer Res., May 1, 2003; 9(5): 1877 - 1884. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Richards, J. Karpilow, C. Dunn, I. Peterson, A. Maxfield, L. Zharkikh, M. Abedi, A. Hurlburt, J. Hardman, F. Hsu, et al. Genetic Selection for Modulators of a Retinoic-Acid-Responsive Reporter in Human Cells Genetics, March 1, 2003; 163(3): 1047 - 1060. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Ross Retinoid Production and Catabolism: Role of Diet in Regulating Retinol Esterification and Retinoic Acid Oxidation J. Nutr., January 1, 2003; 133(1): 291S - 296. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Farhana, M. Dawson, A. K. Rishi, Y. Zhang, E. Van Buren, C. Trivedi, U. Reichert, G. Fang, M. W. Kirschner, and J. A. Fontana Cyclin B and E2F-1 Expression in Prostate Carcinoma Cells Treated with the Novel Retinoid CD437 Are Regulated by the Ubiquitin-mediated Pathway Cancer Res., July 1, 2002; 62(13): 3842 - 3849. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. C. Tibaduiza, J. C. Fleet, R. M. Russell, and N. I. Krinsky Excentric Cleavage Products of {beta}-Carotene Inhibit Estrogen Receptor Positive and Negative Breast Tumor Cell Growth In Vitro and Inhibit Activator Protein-1-Mediated Transcriptional Activation J. Nutr., June 1, 2002; 132(6): 1368 - 1375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. Karamouzis, V. G. Gorgoulis, and A. G. Papavassiliou Transcription Factors and Neoplasia: Vistas in Novel Drug Design Clin. Cancer Res., May 1, 2002; 8(5): 949 - 961. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Budhu and N. Noy Direct Channeling of Retinoic Acid between Cellular Retinoic Acid-Binding Protein II and Retinoic Acid Receptor Sensitizes Mammary Carcinoma Cells to Retinoic Acid-Induced Growth Arrest Mol. Cell. Biol., April 15, 2002; 22(8): 2632 - 2641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kamitani, S. Taniura, K. Watanabe, M. Sakamoto, T. Watanabe, and T. Eling Histone acetylation may suppress human glioma cell proliferation when p21WAF/Cip1 and gelsolin are induced Neuro-oncol, April 1, 2002; 4(2): 95 - 101. [Abstract] [PDF]
|
|
|
|
|
|
E. R. Smith, C. D. Capo-chichi, J. He, J. L. Smedberg, D.-H. Yang, A. H. Prowse, A. K. Godwin, T. C. Hamilton, and X.-X. Xu Disabled-2 Mediates c-Fos Suppression and the Cell Growth Regulatory Activity of Retinoic Acid in Embryonic Carcinoma Cells J. Biol. Chem., December 7, 2001; 276(50): 47303 - 47310. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Dow, J. Hendley, A. Pirkmaier, E. A. Musgrove, and D. Germain Retinoic Acid-mediated Growth Arrest Requires Ubiquitylation and Degradation of the F-box Protein Skp2 J. Biol. Chem., November 30, 2001; 276(49): 45945 - 45951. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R A Sharma, A J Gescher, K J O'Byrne, and W P Steward Familiar drugs may prevent cancer Postgrad. Med. J., August 1, 2001; 77(910): 492 - 497. [Abstract] [Full Text] [PDF]
|
|